SUBSCRIBE
SUBSCRIBE
News   Business

Roche Holding AG Said to Return Diabetes Drug Rights to Ipsen Because of Side Effects

February 1, 2011 | 
1 min read
Bloomberg -- Roche Holding AG returned rights to the experimental diabetes drug taspoglutide to developer Ipsen SA after patients dropped out of trials because of side effects, according to two people with knowledge of the matter.
Alliances
Ipsen Biopharmaceuticals, Inc.
MORE ON THIS TOPIC
Hands reach out to each other. Handshake between human and robot. Cooperation with artificial intelligence. Shaking hands. Make a deal. Successful agreement. Modern collage
Artificial intelligence
Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact
June 17, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more
June 17, 2026
 · 
2 min read
 · 
Jef Akst
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Neumora, enGene cut staff in cost-saving initiatives
June 16, 2026
 · 
61 min read
 · 
BioSpace Editorial Staff
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Drug Development
Neumora discards depression asset, lays off staffers after pair of late-stage flops
June 15, 2026
 · 
2 min read
 · 
Gabrielle Masson